Briefing
Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients.
NeXT Personal was applied to 24 people with metastatic esophagogastric cancer in the phase 2 KeyLargo study, and every patient was ctDNA-positive at baseline.
- Design: Evidence level 3
- Assay: NeXT Personal
Scientific ReportsPubMed 41872254DOI 10.1038/s41598-026-43178-4